Phase II Study of High-dose Methylprednisolone and Rituximab in Previously Treated Patients With High Risk Chronic B Lymphocytic Leukemia.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Methylprednisolone; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 25 Feb 2012 Actual end date changed from Dec 2009 to Jul 2011 as reported by European Clinical Trials Database.
- 24 Feb 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.
- 24 Feb 2010 Actual patient number (29) added as reported by ClinicalTrials.gov.